Vasogen-- VAS on TSE | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy
Vasogen-- VAS on TSE

An SI Board Since January 1997

Posts	SubjectMarks	Bans	Symbol
377	19	0	VSGN

Emcee: caly	Type: Unmoderated

Introduction Market Data Compact

Company Stock: NASD:VSGN TSX: VAS

Website: vasogen.com

SEDAR Filings: sedar.com

Press Releases: vasogen.com

Product Pipeline: vasogen.com

Shares Outstanding: 72 million at March 4, 2004(fully diluted: 76 million)

Based on the competitive products listed in a biotech report, here's a link to Yahoo giving quotes/news for the companies involved in developing similar drugs/treatments to Vasogen's Celacade.

finance.yahoo.com

Here are the phases I think they're in based on PRs and info from the websites.

Vasogen's Celacade - Phase III est. comp Q2 2005
Atherogenics AGI-1067 - Phase III est. comp Q1 2006
GSK's Lp-PLA2 inhibitor - Phase II
DeCode's DG031 - Phase IIa - 2+ years out
Vertex's VX702 - Phase IIa
Incyte's INC3284 - Phase I

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
377	Vasogen is not dead and buried, probably best performing stock on TSX over the p	Stephen O	-	12/20/2007
376	<img src='http://us.i1.yimg.com/us.yimg.com/i/nt/ic/ut/bsc/warn16_1.gif&#	Done, gone.	-	1/26/2007
375	>>>You aren't getting it. You have no idea how to do stats do you?	Pluvia	-	9/11/2006
374	<i>not only are you off mark with that shot, but you're so far off you	Clarksterh	-	9/11/2006
373	>>I understand the implicit putative MOA for their stat sig subgroup. But	Pluvia	-	9/11/2006
372	<i>Obviously damaged heart tissue seems to be key. Given VSGN's admiss	Clarksterh	-	9/11/2006
371	I suggest you read the data more carefully. ~ Remove prior heart attack from	Pluvia	-	9/11/2006
370	<i>They only split into classes II, III and IV basically.</i> They	Clarksterh	-	9/7/2006
369	I still don't understand. They only split into classes II, III and IV basi	Stephen O	-	9/7/2006
368	<i>Doesn't it just mean that celacade did not work worth a damn with t	Clarksterh	-	9/7/2006
367	Doesn't it just mean that celacade did not work worth a damn with the others	Stephen O	-	9/7/2006
366	<i>1. likely not data mining - BECAUSE 2. they were pre-determined subgrou	Clarksterh	-	9/7/2006
365	1. likely not data mining - BECAUSE 2. they were pre-determined subgroups AND	Pluvia	-	9/6/2006
364	'Interesting new look at the CHF trial. Keep in mind that, although this loo	Done, gone.	-	9/4/2006
363	<img src='http://www.novell.com/coolblogs/wp-content/uploads/2006/04/foot	Done, gone.	-	9/3/2006
362	New Data from Vasogen's ACCLAIM Trial in Heart Failure Presented at World Co	Pluvia	-	9/3/2006
361	Vasogen heart therapy cuts risk in 70 pct of patients Sun Sep 3, 2006 5:10am ET1	Pluvia	-	9/3/2006
360	Why bother? Matter of time before their remaining pennies run out and time fo	Done, gone.	-	7/16/2006
359	For more discussion on Vasogen, check out the following links: Yahoo! messages.	Jackboot27	-	7/15/2006
358	Phase III Acclaim trial of the drug Celacade failed to meet its primary endpoint	Done, gone.	-	6/26/2006
357	If Acclaim results are successful, I expect a gap up of $3 a share	Stephen O	-	6/15/2006
356	<i> I expect the share price to be at least $3.00 by September.</i>	Done, gone.	-	6/15/2006
355	Nice job, my "sixth sense" tells me you will win huge on this one IMO	DaiTN	-	6/15/2006
354	<i>we remain on track to release the top-line results from the ACCLAIM tri	Done, gone.	-	6/14/2006
353	LOL [graphic]	russet	-	6/8/2006

Go to reply# or date (mm/dd/yy):